-The Guardian Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms. A decade or so ago, it was mostly about access to Aids drugs. Firms...
More »SEARCH RESULT
Total Matching Records found : 455
EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal
-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...
More »Calling big pharma’s bluff -Dwijen Rangnekar
-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...
More »European Union-India FTA may hit generic medical industry-Rema Nagarajan
-The Times of India The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade...
More »Response to 'A Cost-Benefit Analysis of UID'-Sumathi Chandrashekaran, Shekhar H Kumar, Smriti Parsheera, Ila Patnaik, Madhavi Pundit, Suyash Rai and Ajay Shah
-Economic and Political Weekly A debate on the study "A Cost-Benefit Analysis of Aadhaar" conducted by the National Institute of Public Finance and Policy which was discussed in the EPW of 2 February 2013. Sumathi Chandrashekaran, Shekhar H Kumar, Smriti Parsheera, Ila Patnaik, Madhavi Pundit, Suyash Rai, Ajay Shah A debate on the study “A Cost-Benefit Analysis of Aadhaar” conducted by the National Institute of Public Finance and Policy which was discussed in...
More »
